Cite
Prospective head-to-head comparative phase 3 study between 18F-fluciclovine and 68Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer
MLA
Jeremie Calais, et al. “Prospective Head-to-Head Comparative Phase 3 Study between 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT in Patients with Early Biochemical Recurrence of Prostate Cancer.” Journal of Clinical Oncology, vol. 37, May 2019, p. 5014. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4b801b4f9b9dbd3fe79e4ed4e9e0b058&authtype=sso&custid=ns315887.
APA
Jeremie Calais, Hossein Jadvar, Magnus Dahlbom, Matthias Eiber, Wolfgang P. Fendler, Robert E. Reiter, Tore Bach-Gansmo, Roger Slavik, Tom Hope, Jeannine Gartmann, Christoph Rischpler, Tristan Grogan, Matthew Rettig, Bital Savir-Baruch, Johannes Czernin, Francesco Ceci, Cristina Nanni, David Elashoff, & Michael S Hofman. (2019). Prospective head-to-head comparative phase 3 study between 18F-fluciclovine and 68Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer. Journal of Clinical Oncology, 37, 5014.
Chicago
Jeremie Calais, Hossein Jadvar, Magnus Dahlbom, Matthias Eiber, Wolfgang P. Fendler, Robert E. Reiter, Tore Bach-Gansmo, et al. 2019. “Prospective Head-to-Head Comparative Phase 3 Study between 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT in Patients with Early Biochemical Recurrence of Prostate Cancer.” Journal of Clinical Oncology 37 (May): 5014. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4b801b4f9b9dbd3fe79e4ed4e9e0b058&authtype=sso&custid=ns315887.